Life Science Investing Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome
Life Science Investing Acadia Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
Life Science Investing Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview
Life Science Investing Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025
Life Science Investing Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint
Life Science Investing Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology
Life Science Investing Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635
Life Science Investing Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer
pharmaceutical investing ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Exclusive License Agreement
pharmaceutical investing ACADIA Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for NUPLAZID (Pimavanserin)
Surface Metals Inc. Engages Barwicki Investor Relations to Lead Strategic Investor Relations and Shareholder Communication Program
Spartan Metals Provides Encouraging Drill Assay Results for Tungstonia Tailings at its Eagle Project, Nevada
Homerun Resources Inc. 100% Owned Subsidiary Homerun Energy SRL Recognized as Key Innovator by European Commission's Innovation Radar
Cartier Reports Significant Gold Resource Growth At Cadillac With 9,953,000 tonnes at a grade of 2.40g/t Au for 767,800 Ounces Measured and Indicated, a 7% Increase and 35,185,000 tonnes at a grade of 2.14g/t Au for 2,416,900 Ounces Inferred, a 48% Increase
